A Phase 1b, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Camidanlumab Tesirine (ADCT-301) in Patients With Selected Advanced Solid Tumors

What is the purpose of this trial?

This study evaluates ADCT-301 in patients with Selected Advanced Solid Tumors. Patients will participate in a Treatment Period with 3-week cycles and a Follow-up Period every 12 weeks for up to 1 year after treatment discontinuation.



ADC Therapeutics Sarl

Start Date: 11/26/2018

End Date: 07/01/2020

Last Updated: 11/27/2018

Study HIC#: 2000023689

Get Involved

For more information about this study, contact:
Nicole Sinclair
+1 203-737-1889
nicole.sinclair@yale.edu

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 1-877-978-8348.

Trial Image

Investigators

Patricia LoRusso

Principal Investigator

Sub-Investigators